Literature DB >> 23784737

A review of the adverse effects and safety of noradrenergic antidepressants.

Eromona Whiskey1, David Taylor.   

Abstract

There are a variety of noradrenergic antidepressants available, most of which act by inhibiting neuronal noradrenaline re-uptake, although few drugs are specific for this action. Where drugs have numerous actions the adverse effects of noradrenaline reuptake may be difficult to isolate, although in this respect the adverse effects of reboxetine, a specific noradrenaline re-uptake inhibitor, are illuminating. Noradrenergic antidepressants typically cause minor changes in blood and heart rate, sweating and insomnia. Other pharmacological actions shown by non-specific antidepressants may act to worsen or mitigate these adverse effects. Noradrenergic drugs are less likely than selective serotonin reuptake inhibitors (SSRIs) to cause sexual dysfunction but more likely to cause urinary hesitancy. Doubts remain over the relative propensity for antidepressants with different modes of action to cause diabetes and hyponatraemia. Noradrenergic actions do not seem to confer a risk of death in overdose.

Entities:  

Keywords:  Antidepressant agent; adverse drug reaction; noradrenaline

Mesh:

Substances:

Year:  2013        PMID: 23784737     DOI: 10.1177/0269881113492027

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  16 in total

1.  Citalopram-induced hyponatraemia and parkinsonism: potentially fatal side-effects not to be missed.

Authors:  Negin Damali Amiri; Nishan Wijenaike
Journal:  BMJ Case Rep       Date:  2014-11-12

2.  GABAA Receptor Density Is Not Altered by a Novel Herbal Anxiolytic Treatment.

Authors:  Ravid Doron; Avital Sever; Assaf Handelsman; Roni Toledano; Motty Franko; Yafit Hirshler; Alon Shamir; Or Burstein; Moshe Rehavi
Journal:  J Mol Neurosci       Date:  2018-05-08       Impact factor: 3.444

3.  Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.

Authors:  Christoph U Correll; Johan Detraux; Jan De Lepeleire; Marc De Hert
Journal:  World Psychiatry       Date:  2015-06       Impact factor: 49.548

4.  Pharmacological Management of Anxiety Disorders in the Elderly.

Authors:  Elizabeth A Crocco; Sindy Jaramillo; Caroline Cruz-Ortiz; Katherine Camfield
Journal:  Curr Treat Options Psychiatry       Date:  2017-02-10

5.  Predictors of self-medication in Serbian adult population: cross-sectional study.

Authors:  Katica Tripković; Andjelija Nešković; Janko Janković; Marina Odalović
Journal:  Int J Clin Pharm       Date:  2018-03-30

6.  Trends in Prescriptions for Insomnia in a Province in China Between 2015 and 2019.

Authors:  Guodong Lou; Zhenwei Yu; Liying Chen; Yiting Zhou; Lisan Zhang
Journal:  Front Psychiatry       Date:  2022-06-20       Impact factor: 5.435

7.  Erotic stimulus processing under amisulpride and reboxetine: a placebo-controlled fMRI study in healthy subjects.

Authors:  Heiko Graf; Maike Wiegers; Coraline D Metzger; Martin Walter; Georg Grön; Birgit Abler
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

8.  Maternal immune activation epigenetically regulates hippocampal serotonin transporter levels.

Authors:  Sonali N Reisinger; Eryan Kong; Deeba Khan; Stefan Schulz; Marianne Ronovsky; Stefanie Berger; Orsolya Horvath; Maureen Cabatic; Angelika Berger; Daniela D Pollak
Journal:  Neurobiol Stress       Date:  2016-02-24

9.  Milnacipran treatment and potential biomarkers in depressed patients following an initial SSRI treatment failure: a prospective, open-label, 24-week study.

Authors:  Tasuku Hashimoto; Daiji Sakurai; Yasunori Oda; Tadashi Hasegawa; Nobuhisa Kanahara; Tsuyoshi Sasaki; Hideki Komatsu; Junpei Takahashi; Takahiro Oiwa; Yoshimoto Sekine; Hiroyuki Watanabe; Masaomi Iyo
Journal:  Neuropsychiatr Dis Treat       Date:  2015-12-10       Impact factor: 2.570

10.  Inhibition of Phosphodiesterase 4 by FCPR03 Alleviates Lipopolysaccharide-Induced Depressive-Like Behaviors in Mice: Involvement of p38 and JNK Signaling Pathways.

Authors:  Hui Yu; Zhengqiang Zou; Xiaolin Zhang; Wanli Peng; Chen Chen; Yicheng Ye; Jiangping Xu; Haitao Wang
Journal:  Int J Mol Sci       Date:  2018-02-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.